➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

McKesson
Moodys
Express Scripts
Johnson and Johnson
Merck
Boehringer Ingelheim

Last Updated: January 28, 2021

DrugPatentWatch Database Preview

COMBIVENT Drug Profile

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

When do Combivent patents expire, and what generic alternatives are available?

Combivent is a drug marketed by Boehringer Ingelheim and is included in two NDAs. There are eight patents protecting this drug.

The generic ingredient in COMBIVENT is albuterol sulfate; ipratropium bromide. There are thirty-eight drug master file entries for this compound. Twelve suppliers are listed for this compound. Additional details are available on the albuterol sulfate; ipratropium bromide profile page.

US ANDA Litigation and Generic Entry Outlook for Combivent

Annual sales in 2018 were $1.0bn, indicating a strong incentive for generic entry.

There is one tentative approval for the generic drug (albuterol sulfate; ipratropium bromide), which indicates the potential for near-term generic launch.

Indicators of Generic Entry

< Available with Subscription >

  Start Trial

Drug patent expirations by year for COMBIVENT
Drug Prices for COMBIVENT

See drug prices for COMBIVENT

Drug Sales Revenue Trends for COMBIVENT

See drug sales revenues for COMBIVENT

Recent Clinical Trials for COMBIVENT

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Ontario Lung AssociationPhase 4
University Medical Center GroningenPhase 4
Wouter van GeffenPhase 4

See all COMBIVENT clinical trials

US Patents and Regulatory Information for COMBIVENT

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Boehringer Ingelheim COMBIVENT albuterol sulfate; ipratropium bromide AEROSOL, METERED;INHALATION 020291-001 Oct 24, 1996 DISCN No No   Start Trial   Start Trial   Start Trial
Boehringer Ingelheim COMBIVENT RESPIMAT albuterol sulfate; ipratropium bromide SPRAY, METERED;INHALATION 021747-001 Oct 7, 2011 RX Yes Yes   Start Trial   Start Trial Y   Start Trial
Boehringer Ingelheim COMBIVENT RESPIMAT albuterol sulfate; ipratropium bromide SPRAY, METERED;INHALATION 021747-001 Oct 7, 2011 RX Yes Yes   Start Trial   Start Trial Y   Start Trial
Boehringer Ingelheim COMBIVENT RESPIMAT albuterol sulfate; ipratropium bromide SPRAY, METERED;INHALATION 021747-001 Oct 7, 2011 RX Yes Yes   Start Trial   Start Trial Y   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Merck
Mallinckrodt
Colorcon
McKesson
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.